REGiMMUNE Presents New ToleroVax Data at the 2010 American Transplant Congress

A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer

Invariant natural killer T cell-based immunotherapy for cancer

REGiMMUNE Presented Enhanced Efficacy Data in Preclinical Transplantation Models at the 2009 American Transplant Congress

A Phase I Study of Alpha-Galactosylceramide (KRN7000)–Pulsed Dendritic Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer

KRN7000 in Treating Patients With Solid Tumors- lung cancer

KRN7000 in Chronic Hepatitis B

Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma

Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection

Combination therapy of in vitro-expanded natural killer T cells and α-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma.

Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in
highly coordinated secondary activation of acquired and innate immunity